More on Alexion (ALXN -1.2%) Q1: Net profit +69% to $45.4M, boosted by strong sales of its...


More on Alexion (ALXN -1.2%) Q1: Net profit +69% to $45.4M, boosted by strong sales of its Soliris drug for the treatment of a rare blood disorder. Alexion also ups its guidance and now expects FY EPS of $1.65-$1.75 vs. $1.60-$1.70 prior and revenue of $1.065B-$1.085B vs $1.04B-$1.07B. Analysts forecast EPS of $1.74 on revenue of $1.07B.

From other sites
Comments (2)
  • montanamark
    , contributor
    Comments (1455) | Send Message
     
    not good enough for someone - heading below 90
    24 Apr 2012, 10:38 AM Reply Like
  • Charlieboy Stevens
    , contributor
    Comments (84) | Send Message
     
    Buy em based upon 25% plus sales and operating income growth. ALXN does even better. This is either a buy out soon or another ISRG. Go Go ALXN, I need more retirement funds. Charlieboy Stevens
    24 Apr 2012, 02:54 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs